These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3925170)

  • 1. An in vivo assessment of factor VIII concentrates.
    Rock G; Tittley P; Fuller V
    JAMA; 1985 Aug; 254(6):777-80. PubMed ID: 3925170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [in vivo reappearance of injected cryoprecopitate (factor VIII concentrates) in patients with hemophilia A].
    Kuble M; Wegner H; Cron D
    Z Gesamte Inn Med; 1973 Oct; 28(20):608-14. PubMed ID: 4767194
    [No Abstract]   [Full Text] [Related]  

  • 3. [Study of the "in vivo" activity of factor VIII or factor IX after injection of several concentrates: practical applications].
    Allain JP
    Nouv Rev Fr Hematol; 1972; 12(2):241-9. PubMed ID: 4264617
    [No Abstract]   [Full Text] [Related]  

  • 4. Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.
    Bennett B; Ratnoff OD
    J Clin Invest; 1972 Oct; 51(10):2593-6. PubMed ID: 4626847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hemostatic management in hemophilia A. Usefulness of APTT and TEG as a method for monitoring Factor VIII concentrates].
    Watanabe S; Ito S; Igarashi S; Itamoto M; Harada N; Kanazawa M; Sato M; Yasukouji T
    Shoni Shikagaku Zasshi; 1985; 23(3):760-8. PubMed ID: 3938858
    [No Abstract]   [Full Text] [Related]  

  • 6. In vivo recovery of factor VIII: a comparison of one-stage and two-stage assay methods.
    Nilsson IM; Kirkwood TB; Barrowcliffe TW
    Thromb Haemost; 1979 Dec; 42(4):1230-9. PubMed ID: 120619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates.
    Kasper CK; Kim HC; Gomperts ED; Smith KJ; Salzman PM; Tipping D; Miller R; Montgomery RM
    Thromb Haemost; 1991 Dec; 66(6):730-3. PubMed ID: 1796419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytic variability due to change of deficient plasma vials: application to one-stage clotting factor VIII assay.
    Nougier C; Sobas F; Nguyen TK; Carage ML; Lienhart A; Négrier C
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):151-4. PubMed ID: 21192255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
    Mazurier C; Parquet-Gernez A; Goudemand M
    Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance of cryoprecipitated factor VIII in canine hemophilia A.
    Aufderheide WM; Skinner SF; Kaneko JJ
    Am J Vet Res; 1975 Apr; 36(4 Pt.1):367-70. PubMed ID: 1124873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current clinical aspects in hemophilia treatment].
    Meili EO
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1332-41. PubMed ID: 2508219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrepancies in measured factor VIII activity in patients treated with factor VIII concentrate of human or porcine origin.
    Teitel JM; Lau HK; Garvey MB
    Thromb Haemost; 2002 Jul; 88(1):159-60. PubMed ID: 12152659
    [No Abstract]   [Full Text] [Related]  

  • 14. The treatment of classical hemophilia with factor 8 concentrates.
    Waterbury L; Frenkel EP
    Clin Anesth; 1968; 3():288-97. PubMed ID: 4902367
    [No Abstract]   [Full Text] [Related]  

  • 15. Kinetic analysis of bovine factor VIII in the hemophilic dog.
    Gentry PA; Kirby EP; Gentry RD
    Thromb Haemost; 1981 Aug; 46(2):485-8. PubMed ID: 6795739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII half-life and clinical phenotype of severe hemophilia A.
    van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
    Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lyophilized cryoprecipitate for children with hemophilia A.
    Nuchprayoon I; Sahasittiwat S; Kittikalayawong A; Chantanakajornfung A
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S293-7. PubMed ID: 12188426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coincident classic hemophilia and "idiopathic" thrombocytopenic purpura in patients under treatment with concentrates of antihemophilic factor (factor VIII).
    Ratnoff OD; Menitove JE; Aster RH; Lederman MM
    N Engl J Med; 1983 Feb; 308(8):439-42. PubMed ID: 6401839
    [No Abstract]   [Full Text] [Related]  

  • 19. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of transfused factor VIII in hemophilic patients treated with epsilon aminocaproic acid.
    Weiss AE; Webster WP; Strike LE; Brinkhous KM
    Transfusion; 1976; 16(3):209-14. PubMed ID: 936268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.